Summary

In this truncated replay, Dr. Shyam Joshi explores the intersection between allergy and dermatology—focusing on how chronic spontaneous urticaria (CSU), atopic dermatitis, and food allergies often overlap. Learn how emerging biologics like omalizumab and dupilumab are reshaping treatment decisions, why comorbidities matter, and how collaboration between allergists and dermatologists creates better outcomes for patients with complex allergic and dermatologic conditions.

This episode dives into real-world case studies, FDA updates on antihistamines, and the multidisciplinary approach to managing eczema and CSU in pediatric and adult populations.

Takeaways

- FDA Advisory on Antihistamines: Long-term use of cetirizine or levocetirizine can lead to rebound pruritus upon discontinuation—but gradual tapering minimizes symptoms.
- Biologic Selection Depends on Comorbidities:
- Omalizumab is effective for IgE-mediated food allergies and chronic urticaria.
- Dupilumab is preferred for patients with eosinophilic esophagitis (EoE) or moderate-to-severe atopic dermatitis.
- CSU Is Systemic: Symptoms may extend beyond hives—impacting joints, sleep, and energy levels.
- Comorbid Conditions Are Common: Up to 20 % of CSU patients have asthma, allergic rhinitis, or food allergies; identifying these helps guide treatment and patient education.
- Unified Messaging Builds Trust: Consistent communication from both dermatologists and allergists reduces unnecessary testing and supports adherence to treatment plans.

Chapters

00:00 - Introduction: Bridging Allergy and Dermatology
00:45 - Case Study: An 18-Year-Old with Chronic Urticaria
02:00 - FDA Warning: Antihistamine Withdrawal Itch
03:45 - Selecting the Right Biologic: Food Allergy Considerations
04:45 - Eosinophilic Esophagitis and CSU
05:35 - The Systemic Nature of CSU
06:40 - Comorbidities in CSU and Atopic Patients
07:30 - Multidisciplinary Collaboration in Practice
08:00 - Closing Thoughts & Educational Disclaimer